Veronesi U, Bonadonna G, Zurrida S, Galimberti V, Greco M, Brambilla C, Luini A, Andreola S, Rilke F, Raselli R
Istituto Nazionale Tumori, Milano, Italy.
Ann Surg. 1995 Nov;222(5):612-8. doi: 10.1097/00000658-199511000-00002.
The authors evaluated the utility of preoperative chemotherapy in patients with large size breast carcinoma, with a view to rendering a conservative surgical approach possible or easier.
Two hundred twenty-six of 227 patients with breast cancer involving a tumor larger than 3 cm at greatest dimension were candidates for mastectomy. They were treated with various primary preoperative chemotherapies and evaluated for surgery.
After administering various chemotherapeutic regimens, the authors reevaluated the patients' conditions clinically and radiologically to plan definitive surgical treatment. If the tumor diameter was sufficiently reduced, quadrantectomy was planned; otherwise, mastectomy was performed. Complete axillary lymph node dissection was done in all cases.
In 90% of the cases, the size reduction was sufficient to justify breast conservation; in 10%, tumor size did not decrease enough or increased, thus mastectomy was performed. In 11.8% of the cases, the tumor was no longer identifiable at surgical inspection, and in 3.5% no tumor was found on microscopic examination. Axillary lymph nodes were free of metastases in 39% of cases. Twelve local recurrences occurred among the 203 patients treated with breast conservation (5.9%) and five among the 23 patients treated with mastectomy (21.7%).
Primary chemotherapy can expand the indication for breast conservation to large tumors; careful attention, however, must be paid to surgical technique. The position of the tumor should be marked with tattoo points on the skin before chemotherapy. The macroscopic extent of the tumor regression must be evaluated carefully, and multiple frozen section biopsies may be needed. The margins of the resected breast should be evaluated microscopically. All microcalcifications present before treatment must be resected. The skin incision and mammary resection must fulfill criteria of radicality as well as good cosmetic outcome.
作者评估术前化疗在大尺寸乳腺癌患者中的效用,以期使保守手术方法可行或更易实施。
227例最大径大于3 cm的乳腺癌患者中,226例为乳房切除术候选者。他们接受了各种原发性术前化疗并接受手术评估。
在给予各种化疗方案后,作者对患者的病情进行临床和影像学重新评估,以规划确定性手术治疗。如果肿瘤直径充分缩小,则计划行象限切除术;否则,进行乳房切除术。所有病例均行腋窝淋巴结清扫术。
90%的病例中,肿瘤大小缩小到足以支持保乳治疗;10%的病例中,肿瘤大小缩小不足或增大,因此进行了乳房切除术。11.8%的病例在手术检查时肿瘤无法辨认,3.5%的病例在显微镜检查时未发现肿瘤。39%的病例腋窝淋巴结无转移。203例接受保乳治疗的患者中有12例发生局部复发(5.9%),23例接受乳房切除术的患者中有5例发生局部复发(21.7%)。
原发性化疗可将保乳治疗的适应证扩大到大型肿瘤;然而,必须密切关注手术技术。化疗前应在皮肤上用纹身点标记肿瘤位置。必须仔细评估肿瘤退缩的宏观范围,可能需要多次冰冻切片活检。应在显微镜下评估切除乳房的切缘。治疗前存在的所有微钙化灶均必须切除。皮肤切口和乳腺切除必须符合根治性标准以及良好的美容效果。